) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1
Search Results
HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer
Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo
Introduction to the Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment
The Cancer Center Cessation Initiative Coordinating Center and Expert Advisory Panel
smokers at the time of diagnosis. 5 Although compelling data have shown that quitting smoking after a cancer diagnosis leads to better health and quality of life outcomes, a 2009 survey reported that only 38% of NCI Cancer Centers recorded smoking as a
A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity
Krisda H. Chaiyachati, Diana Krause, Jessica Sugalski, Evan M. Graboyes, and Lawrence N. Shulman
widened racial and income disparities in cancer treatment outcomes. 19 – 21 Although national organizations such as the National Academies of Sciences, Engineering, and Medicine have identified transportation insecurity as a key social risk factor, 22
CLO22-035: Treatment Outcome of Ruxolitinib and Decitabine Combination Chemotherapy Among Transplant Ineligible Advanced Stage Myeloproliferative Neoplasm: A Meta-analysis
Jacqueline Agustin and Ma. Rosario Irene D. Castillo
not eligible for transplant, hence chemotherapy is a frequently chosen alternative. This meta-analysis sheds light on treatment outcomes of advanced stage myeloproliferative neoplasm patients treated with combination decitabine and ruxolitinib
CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data
Abdenour Nabid, Nathalie Carrier, Eric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Marc-André Brassard, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, and Luis Souhami
Purpose/Objective(s): To compare the magnitude of differences in outcomes between intermediate and high risk prostate cancer (IRPC – HRPC) using NCCN classification in two concurrent phase III trials performed in the same population. Materials
Testicular Cancer Survivorship
Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis
long-term adverse health outcomes (AHOs) among TCS is critically important for the development of risk-stratified, evidence-based follow-up guidelines. A multi-institutional study 40 among North American TCS (median age, 37 years) after cisplatin
HSR23-090: Racial Differences in Outcomes of Osimertinib in Patients With EGFR-Positive Non–Small Cell Lung Cancer in a Real World US Population
Jeffrey Zhong, Jaime Abe Perez, Annie Liang Zhang, Debora Bruno, and Melinda Laine-Hsu
mortality when compared to non-Asian patients with EGFR-positive NSCLC in a real-world US population. Further research is required to determine whether this association stems from a biological or non-biological cause. Table. Outcomes between AANHPI
HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting
Yu-Jing Huang, Paula D. Ryan, Gregory L. Price, Gebra Cuyun Carter, Kristin M. Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Jonathan Rajkumar, and Lavanya Sudharshan
) patients (pts). This study examined real-world pt characteristics, select adverse events (AEs), and related outcomes of these pts. Methods: Female pts in the United States Oncology Network’s iKnowMedTM electronic health records (EHR) database were
CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy
Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, and Russell Hales
Background: Although isolated locoregional recurrence (iLR) for non-small cell lung cancer (NSCLC) is relatively common, the optimal therapy for iLR is undefined. It is feasible that patients with iLR may have equal or superior outcomes to patients
CGE21-031: Genomic Biomarker Testing, Treatments, and Survival Outcomes Among Patients With Advanced or Metastatic NSCLC in the US: A Retrospective Cohort Study
Yajun Zhu, Yimei Han, Naleen Raj Bhandari, and Lisa Hess
Objectives: This study identified factors associated with genomic biomarker testing (“tested” vs “not tested”) and examined the association of the receipt of treatment that is guided by genomic biomarker testing results with survival outcomes among
